<DOC>
	<DOCNO>NCT00950300</DOCNO>
	<brief_summary>In open-label multicenter trial , participant operable locally advanced breast cancer randomize pre-operative treatment 8 cycle chemotherapy ( 4 cycle docetaxel follow 4 cycle 5-fluorouracil , epirubicin , cyclophosphamide ) concurrent either SC Herceptin IV Herceptin . After surgery , participant receive 10 cycle SC IV Herceptin per randomization complete 1 year treatment . All cycle 21 day length . After end study treatment , participant follow safety efficacy 5 year disease recurrence , whichever early .</brief_summary>
	<brief_title>A Study Compare Subcutaneous ( SC ) Versus Intravenous ( IV ) Administration Herceptin ( Trastuzumab ) Women With Human Epidermal Growth Factor Receptor ( HER ) 2-Positive Early Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Adult woman great equal ( ≥ ) 18 year age Nonmetastatic primary invasive adenocarcinoma breast clinical stage I IIIC , include inflammatory multicentric/multifocal breast cancer , tumor size ≥1 centimeter ( cm ) ultrasound ≥2 cm palpation , centrally confirm HER2positive ( immunohistochemical score [ IHC ] 3+ situ hybridization [ ISH ] positive ) At least 1 measurable lesion breast lymph node ( ≥1 cm ultrasound ≥2 cm palpation ) , except inflammatory carcinoma ( T4d ) Baseline leave ventricular ejection fraction ( LVEF ) ≥55 % Eastern Cooperative Oncology Group ( ECOG ) status 0 1 Adequate organ function Baseline History prior ( ipsilateral and/or contralateral ) invasive breast carcinoma Past current history malignant neoplasm , except curatively treat basal squamous cell carcinoma skin situ carcinoma cervix Metastatic disease Any prior therapy anthracyclines Prior antiHER2 therapy biologic immunotherapy Serious cardiac illness Pregnant lactating woman</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>